000282970 001__ 282970
000282970 005__ 20251219154046.0
000282970 0247_ $$2doi$$a10.1177/18796397251401745
000282970 0247_ $$2pmid$$apmid:41395805
000282970 0247_ $$2ISSN$$a1879-6397
000282970 0247_ $$2ISSN$$a1879-6400
000282970 037__ $$aDZNE-2025-01422
000282970 041__ $$aEnglish
000282970 082__ $$a610
000282970 1001_ $$0P:(DE-2719)2812578$$aAziz, N. Ahmad$$b0$$eFirst author
000282970 245__ $$aβ-Blocker effects in huntington's disease: A caution on clinical interpretation.
000282970 260__ $$aAmsterdam$$bIOS Press$$c2025
000282970 3367_ $$2DRIVER$$aarticle
000282970 3367_ $$2DataCite$$aOutput Types/Journal article
000282970 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1766155162_31937
000282970 3367_ $$2BibTeX$$aARTICLE
000282970 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282970 3367_ $$00$$2EndNote$$aJournal Article
000282970 520__ $$aA recent retrospective analysis of Enroll HD data suggesting β-blockers slow Huntington's disease progression has triggered patient demand but requires caution. The findings rely solely on small observational subsets and are vulnerable to bias and confounding. A prior Mendelian-randomization study found no causal link between β-blockers and HD onset; instead, genetically higher blood pressure was associated with later onset, raising concern that β-blockers' BP-lowering effects could be harmful. HD patients also have lower hypertension rates, and β-blockers carry risks such as depression and bradycardia. Given their heterogeneous mechanisms, rigorous experimental and clinical trials are needed before any clinical recommendations.
000282970 536__ $$0G:(DE-HGF)POF4-354$$a354 - Disease Prevention and Healthy Aging (POF4-354)$$cPOF4-354$$fPOF IV$$x0
000282970 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000282970 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282970 650_7 $$2Other$$abioethics
000282970 650_7 $$2Other$$abiostatistics
000282970 650_7 $$2Other$$aclinical care
000282970 650_7 $$2Other$$aclinical trials
000282970 650_7 $$2Other$$aethics
000282970 7001_ $$00000-0002-9853-4902$$aClaassen, Daniel$$b1
000282970 7001_ $$00000-0001-5488-1200$$aPetersén, Åsa$$b2
000282970 7001_ $$0P:(DE-2719)9001116$$aWeydt, Patrick$$b3$$eLast author
000282970 7001_ $$0P:(DE-HGF)0$$aNetwork, European Huntington's Disease$$b4
000282970 7001_ $$0P:(DE-HGF)0$$aGroup, Huntington Study$$b5
000282970 773__ $$0PERI:(DE-600)2673033-9$$a10.1177/18796397251401745$$gp. 18796397251401745$$p-$$tJournal of Huntington's disease$$vAdvance online publication$$x1879-6397$$y2025
000282970 8564_ $$uhttps://pub.dzne.de/record/282970/files/DZNE-2025-1422_Restricted.pdf
000282970 8564_ $$uhttps://pub.dzne.de/record/282970/files/DZNE-2025-1422_Restricted.pdf?subformat=pdfa$$xpdfa
000282970 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812578$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000282970 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001116$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000282970 9131_ $$0G:(DE-HGF)POF4-354$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Prevention and Healthy Aging$$x0
000282970 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000282970 9141_ $$y2025
000282970 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ HUNTINGTONS DIS : 2022$$d2024-12-17
000282970 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000282970 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000282970 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-17
000282970 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-17
000282970 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000282970 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-17
000282970 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000282970 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-17
000282970 920__ $$lyes
000282970 9201_ $$0I:(DE-2719)1011001$$kClinical Research (Bonn)$$lClinical Research Coordination$$x0
000282970 9201_ $$0I:(DE-2719)5000071$$kAG Aziz$$lPopulation & Clinical Neuroepidemiology$$x1
000282970 980__ $$ajournal
000282970 980__ $$aVDB
000282970 980__ $$aI:(DE-2719)1011001
000282970 980__ $$aI:(DE-2719)5000071
000282970 980__ $$aUNRESTRICTED